Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes
Clinical Lymphoma Myeloma and Leukemia · 2024
DOI: 10.1016/j.clml.2023.09.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024. Verfasst von John Mascarenhas und 13 weiteren Autor:innen. Beteiligte Einrichtung: The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: john.mascarenhas@mssm.edu. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Nitriles, Pyrazoles, Pyrimidines. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bristol-Myers Squibb.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: john.mascarenhas@mssm.edu.
- Guy's and St Thomas' NHS Foundation Trust, London, UK.
- Cardinal Health, Dublin, OH.
- Bristol Myers Squibb, Princeton, NJ.
- Cleveland Clinic Taussig Cancer Institute, Cleveland, OH.
Förderung
- Bristol-Myers Squibb
Zitieren
APA
Mascarenhas, J., Harrison, C., Schuler, T. A., Liassou, D., Garretson, M., Miller, T. A., Mahadevan, S., McBride, A., Tang, D., DeGutis, I. S., Abraham, P., Kish, J., Feinberg, B. A., & Gerds, A. T. (2024). Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2023.09.008
Vancouver
Mascarenhas J, Harrison C, Schuler TA, Liassou D, Garretson M, Miller TA, et al. Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes. Clinical Lymphoma Myeloma and Leukemia. 2024. doi:10.1016/j.clml.2023.09.008
BibTeX
@article{Mascarenhas2024,
author = {Mascarenhas, John and Harrison, Claire and Schuler, Tammy A and Liassou, Djibril and Garretson, Marné and Miller, Taavy A and Mahadevan, Sankar and McBride, Ali and Tang, Derek and DeGutis, Irene S and Abraham, Pranav and Kish, Jonathan and Feinberg, Bruce A and Gerds, Aaron T},
title = {Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2024},
doi = {10.1016/j.clml.2023.09.008}
}
EUVIMED